ACOS (The American-European Congress of Ophthalmic Surgery) and Avedro,
Inc. jointly announced today the initiation of a Phase 3, multi-center,
randomized, controlled evaluation to study accelerated corneal collagen
cross-linking in eyes with keratoconus or corneal ectasia after
refractive surgery. ACOS is sponsoring the study, which will be
conducted in 100 clinical centers across the United States. Each of the
100 clinical sites will use Avedro's KXL™ System and VibeX™ (riboflavin
ophthalmic solution) to treat all patients enrolled in the study.
Stephen G. Slade, MD, President of ACOS said, "In the absence of any FDA
approval for corneal cross-linking, ACOS is delighted to partner with
Avedro on this clinical study which allows keratoconic and ectasia
patients across the United States to receive treatment from leading
ophthalmic surgeons using a uniform treatment protocol and the most
highly-developed technology available today."
"Avedro is proud to be associated with ACOS and very pleased our KXL
System and VibeX riboflavin will now be available to patients in 100
clinics throughout the United States as part of this study," said David
Muller, PhD, President and CEO of Avedro. "We now look forward to
working with some of America's top ophthalmologists engaged in the
important clinical work of improving the sight and quality of life of
thousands of keratoconus and ectasia patients."